Novel agents that downregulate EGFR, HER2, and HER3 in parallel

EGFR, HER2, and HER3 contribute to the initiation and progression of human cancers, and are therapeutic targets for monoclonal antibodies and tyrosine kinase inhibitors. An important source of resistance to these agents arises from functional redundancy among EGFR, HER2, and HER3. EGFR family member...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Autores principales: Ferreira, Renan Barroso, Law, Mary Elizabeth, Jahn, Stephan Christopher, Davis, Bradley John, Heldermon, Coy Don, Reinhard, Mary, Castellano, Ronald Keith, Law, Brian Keith
Formato: Artigo
Lenguaje:Inglês
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4496366/
https://ncbi.nlm.nih.gov/pubmed/25865227
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares